zentalis pharmaceuticals

Zentalis Pharmaceuticals Insider Transactions Over The Last Year. Sector: Health Care Industry: Biotechnology. Ongoing Clinical Trials AllZN-c3ZN-d5ZN-c5ZN-e4 ZN-c3 Phase 2 Uterine Serous Carcinoma Study Phase 2 Biomarker-Driven Study Phase 1/2 Solid Tumors Study Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the stock in a transaction dated Tuesday, July 5th. The biopharmaceutical company said the common . He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. Print.

The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company's founding. What does that mean for you, the investor? According to the issued ratings of 6 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 6 buy ratings for ZNTL.

Actively observing the price movement in the last trading, the stock closed the session at $18.94, falling within a range of $18.63 and $21.48.

There are 4 companies in the Zentalis Pharmaceuticals, Inc. corporate family. Zentalis Pharmaceuticals Company Profile . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Our lead product candidate, ZN-c3, is a potentially first-in-class and best-in-class oral Wee1 inhibitor in development for the treatment of advanced solid tumors. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. - Zentalis Pharmaceuticals Peter Huang, PhD Senior Vice President, Discovery Research Zentalis provides an inspiring work environment for both young scientists and biotech veterans. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Read More News; Pipeline. Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is a majority shareholder of Shanghai, China-based Zentera. Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering. October 01, 2020 Executive Employment Agreements. May 31, 2022.

Kimberly Blackwell Board Member May 2022.

General Information: Business: We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It also means that they are potentially on the cusp . Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small. As of June 2022 Zentalis Pharmaceuticals has a market cap of $1.23 Billion . Comparatively, Zentalis Pharmaceuticals has a beta of 2.74 . The proxy statement for the 2022 Annual Meeting of Stockholders (the "Proxy Statement") of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the "Company"), to be held on June 8, 2022 (the "Meeting"), was filed with the Securities and Exchange Commission on April 28, 2022.Since then, there have been developments regarding the management of the Company. Zentalis Pharmaceuticals Inc. (ZNTL) full year performance was -55.68%. Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. It means that they are dealing with a very specific niche. On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Jobs Salaries Interviews. Jobs Salaries Interviews. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Unsolicited resumes sent to Zentalis from . Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares, rose in value on Friday, 05/13/22, with the stock price up by 8.39% to the previous day's close as strong demand from buyers drove the stock to $20.53. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 .

Instead, they specialize in dealing with treatments on the molecular level that are specifically designed to combat cancer. Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid . Investors/Media Home Company Profile. 10275 Science Center Drive Suite 200 San Diego, CA 92121 Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer It focuses on developing clinically differentiated and small molecule therapeutics.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 1359 Broadway Suite 1710 New York, NY 10018 United States zentalis.com. By Chris Wack. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.

Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President. The biopharmaceutical company said the common shares were offered . Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. By Chris Wack. Proceeds from the Series A financing will be used to develop and commercialize three cancer . The President, Anthony Sun, made the biggest insider sale in the last 12 months. | June 18, 2022 Jobs Salaries Interviews. Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Medical Writer Career. In addition to Zentalis, Cam currently serves on the Board of . Popular Careers with Zentalis Job Seekers. Legal Analyst Career. Before joining ZNTL, Blackwell was chief . Jobs Salaries Interviews. The company aims to address major unmet medical needs for patients with cancer. Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Lists Featuring This Company City of New York Companies (Top 10K) Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. 1-212-433-3791 info@zentalis.com ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals press release (ZNTL): Q4 GAAP EPS of -$1.11 beats by $0.22.As of December 31, 2021, cash, cash equivalents and marketable securities of $339.9M Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) has been assigned an average rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports.

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. That single transaction was for US$1.6m worth of . Vertex Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. The average twelve-month price prediction for Zentalis Pharmaceuticals is $74.43 with a high price target of $120.00 and a low price target of $51.00.

The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Issuer's principal executive offices are located at 1359 Broadway, Suite 1710, New York, New York 10018. Risk and Volatility. June 1, 2022.

Zentalis Pharmaceuticals. Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March. Zentalis Pharmaceuticals is conducting clinical studies evaluating its small molecule therapeutics. Five research analysts have rated the stock with a buy recommendation. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. Premium Investing Services. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Zentalis Pharmaceuticals Company Profile . A high-level overview of Zentalis Pharmaceuticals, Inc. (ZNTL) stock. Science Center. Zentalis Pharmaceuticals has 2 board members and advisors, including Kimberly Blackwell. Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to . Zentalis pulls off speedy $165M IPO amid pandemic-driven . Zentalis is a biopharmaceutical company. Senior Clinical Research Associate Career. Zentalis Pharmaceuticals, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Zentalis Pharmaceuticals ( NASDAQ: ZNTL) intends to raise $130 million from an IPO of its common stock, according to an amended S-1/A registration statement. The stock was sold at an average price of $30.07, for a total transaction of $751,750.00. Enoch Kariuki Board Member Feb 2021. The company is advancing a pipeline of . Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . The Company's products include ZN-c5 and ZN-c3. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . Zentalis Pharmaceuticals, Inc. Chief Operating Officer employment agreement. Presently, Zentalis Pharmaceuticals Inc. shares are logging -71.61% during the 52-week period from high price . Executive Assistant Career. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . Zentalis Pharmaceuticals, LLC. Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 and ZN-c5 and Two Potentially Registrational Trials for ZN-c3, with the. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective . 10835 Road to the Cure Suite 205 San Diego, CA 92121. This makes Zentalis Pharmaceuticals the world's 4057th most valuable company by market cap according to our data. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. For More Information. Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. Zentalis Pharmaceuticals is not your typical pharmaceutical company. Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. It was founded 2014 and headquartered in New York, United States. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . Item 1. To learn more about our ongoing clinical trials, please visit www.clinicaltrials.gov. Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference. Zentalis Pharmaceuticals, Inc.: Bunker Kevin D. (Chief Operating Officer) Sells 25,000 @ Avg Price: $30.07 (Form4)

zentalis pharmaceuticalsnba 2k21 dest roster invisible players